Prognosis of Patients With Stage D1 Prostatic Adenocarcinoma

Abstract

Of 44 patients with clinically localized prostatic adenocarcinoma and regional lymphatic metastases proved by staging pelvic lymphadenectomy 11 were treated by radical prostatectomy, 20 received extended field radiation and 13 were assigned to delayed hormonal therapy. The median survival for the entire group was 39.5% mo. None of the 3 treatments appeared superior in prolonging survival. No enhancement of disease control could be demonstrated in either treatment group. Patients with prostatic adenocarcinoma and positive nodes appear to have equivalent adverse biologic potential and should be considered candidates for treatments designed to produce systemic effect.